Why use telmisartan in patients with diabetes and microalbuminuria? Review article
Article Sidebar
Published:
Jun 30, 2016
Keywords:
hypertension, diabetes, nephropathy, microalbuminuria, hypotensive treatment, ARB, telmisartan
Main Article Content
Abstract
Efficacy of telmisartan in diabetic nephropathy prevention and microalbuminuria reduction has been established in INNOVATION and ONTARGET studies. Long-term use of high dose of 80 mg telmisartan daily leads to inhibition of clinically overt nephropathy in 33% of patients with type 2 diabetes and microalbuminuria.
Article Details
How to Cite
Chmielewski , M., & Kuch, M. (2016). Why use telmisartan in patients with diabetes and microalbuminuria?. Medycyna Faktow (J EBM), 9(2(31), 97-99. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2241
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego 2015; 1(1): 1-70.
2. Yusuf S, Teo KK, Pogue J et al; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
3. Makino H, Haneda M, Babazono T et al. Innovation Study on telmisartan, prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30(6): 1577-1578.
2. Yusuf S, Teo KK, Pogue J et al; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
3. Makino H, Haneda M, Babazono T et al. Innovation Study on telmisartan, prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30(6): 1577-1578.